Clicky

uniQure N.V(UQ1) News

Date Title
Jun 2 uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
May 29 uniQure Presents Clinical Case Study of First Patient Dosed with AMT-260 in Refractory Mesial Temporal Lobe Epilepsy (MTLE)
Apr 21 uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?
Apr 21 FDA grants breakthrough status to uniQure’s Huntington’s disease therapy
Apr 17 uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Feb 20 uniQure N.V. (NASDAQ:QURE) is a favorite amongst institutional investors who own 66%